ScholarIQanswers from OpenAlex & ORCID
Antoine Adenis
ResearcherPublications, citations & collaboration network
Antoine Adenis is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Antoine Adenis have?
ScholarIQindexed works
Antoine Adenis has 326 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Antoine Adenis have?
ScholarIQcitation count
Antoine Adenis has 25,523 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Antoine Adenis?
ScholarIQh-index
Antoine Adenis has an h-index of 51 in OpenAlex.
What is the i10-index of Antoine Adenis?
ScholarIQi10-index
Antoine Adenis has an i10-index of 131 in OpenAlex.
What is the ORCID of Antoine Adenis?
ScholarIQorcid
The ORCID for Antoine Adenis is on the source record.
What is the OpenAlex record for Antoine Adenis?
ScholarIQopenalex
The OpenAlex for Antoine Adenis is on the source record.
What are the most-cited papers on Antoine Adenis?
ScholarIQmost cited works
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun, Lin Shen, Manish A. Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean‐Philippe Metges, Zhigang Li, Sung‐Bae Kim, Byoung Chul Cho, Wasat Mansoor, Shau-Hsuan Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, Hiroki Hara, Luís Carlos Moreira Antunes, Christos Fountzilas, Akihito Tsuji, Victor Castro Oliden, Qi Liu, Sukrut Shah, Pooja Bhagia, Ken Kato
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Yuichiro� Doki, Jaffer A. Ajani, Ken Kato, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Sandra A. Ostoich, Hye R. Kim, Masaki Ueno, Wasat Mansoor, Wen‐Chi Yang, Tianshu Liu, John Bridgewater, Tomoki Makino, Ioannis Xynos, Xuan Liu, Ming Lei, Kaoru Kondo, Apurva Patel, Joseph Gricar, Ian Chau, Yuko Kitagawa, Doki, Yuichiro, Jaffer A. Ajani, Ken Kato, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Hsu, Chih Hung, Antoine Adenis, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Sandra A. Ostoich, Hye R. Kim, Masaki Ueno, Wasat Mansoor, Yang, Wen Chi, Tianshu Liu, John Bridgewater, Tomoki Makino, Ioannis Xynos, Xuan Liu, Ming Lei, Kaoru Kondo, Apurva Patel, Joseph Gricar, Ian Chau, Yuko Kitagawa